Abstract
Multiple myeloma (MM) is a malignancy of terminally differentiated B cells/plasma cells and is primarily located in the bone marrow. Symptomatic multiple myeloma typically presents with osteolyses, anemia, reduced renal function, and/or hypercalcemia. In the case of such MM-related end organ damage, urgent systemic treatment is indicated. In order to prevent end organ damage, current guidelines now recommend treatment initiation already when certain biomarkers are met. Current first-line treatment is based on proteasome inhibition and immunomodulation. Eligible patients still benefit from the addition of high-dose chemotherapy and autologous stem cell transplantation. Radiotherapy and orthopedic interventions play an important role in the treatment of localized skeletal complications. For relapsed MM, five novel agents have been approved in Europe during the last two years. These are second-generation proteasome inhibitors (carfilzomib, ixazomib) as well as first-in-class monoclonal antibodies (daratumumab, elotuzumab) and a histone deacetylase inhibitor (panobinostat). Triple combinations based on the established regimens lenalidomide/dexamethasone and bortezomib/dexamethasone plus one of the novel agents have been shown to si...Continue Reading
References
Jun 22, 2007·The New England Journal of Medicine·Robert A KyleS Vincent Rajkumar
Oct 19, 2007·Blood·Angela DispenzieriS Vincent Rajkumar
Dec 7, 2010·Lancet·Gareth J MorganUNKNOWN National Cancer Research Institute Haematological Oncology Clinical Study Group
Dec 14, 2011·Blood·Kai NebenHartmut Goldschmidt
Oct 26, 2013·Leukemia·S K KumarS V Rajkumar
Nov 2, 2013·Leukemia·H LudwigB Durie
Dec 21, 2013·Annals of Oncology : Official Journal of the European Society for Medical Oncology·M MerzJ Hillengass
Jun 21, 2014·The Lancet Oncology·Gordon CookUNKNOWN National Cancer Research Institute Haemato-oncology Clinical Studies Group
Sep 23, 2014·The Lancet Oncology·Jesús F San-MiguelPaul G Richardson
Dec 3, 2014·The Lancet Oncology·S Vincent RajkumarJesus F San Miguel
Dec 9, 2014·The New England Journal of Medicine·A Keith StewartUNKNOWN ASPIRE Investigators
Jun 3, 2015·The New England Journal of Medicine·Sagar LonialUNKNOWN ELOQUENT-2 Investigators
Oct 4, 2015·Haematologica·Evangelos TerposUNKNOWN European Myeloma Network
Jan 5, 2016·Bone Marrow Transplantation·B DhakalP N Hari
Mar 19, 2016·British Journal of Haematology·Elias K MaiHartmut Goldschmidt
Apr 28, 2016·The New England Journal of Medicine·Philippe MoreauUNKNOWN TOURMALINE-MM1 Study Group
May 25, 2016·Blood·Saad Z UsmaniHareth Nahi
Aug 25, 2016·The New England Journal of Medicine·Antonio PalumboUNKNOWN CASTOR Investigators
Sep 7, 2016·Bone Marrow Transplantation·O LandgrenS Mailankody
Oct 6, 2016·The New England Journal of Medicine·Meletios A DimopoulosUNKNOWN POLLUX Investigators
Apr 6, 2017·The New England Journal of Medicine·Michel AttalUNKNOWN IFM 2009 Study
Apr 22, 2017·Cancer Treatment Reviews·Leo RascheFaith E Davies
Apr 30, 2017·Annals of Oncology : Official Journal of the European Society for Medical Oncology·P MoreauUNKNOWN ESMO Guidelines Committee
Jun 18, 2017·Leukemia·S K KumarB G M Durie
Jul 28, 2017·Blood·Philippe Moreau
Aug 2, 2017·Leukemia·H GoldschmidtP Sonneveld
Jul 1, 2017·Annals of Oncology : Official Journal of the European Society for Medical Oncology·P MoreauUNKNOWN ESMO Guidelines Committee. Electronic address: clinicalguidelines@esmo.org